Eupraxia Pharmaceuticals is trading at $8.53, down 6.32%; reporting identifies no new company-specific catalyst.
- On September 30, shares rose 9.57% to $9.10 after reported 52-week clinical data. Prior-day coverage called the durability results encouraging but did not link them to the October 1 decline.
- XLV fell 1.33% and may add pressure, but there is no evidence it is the primary cause. Current volume was not provided, so trading activity cannot be assessed.